Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company in Finland. It has a pipeline of drug development projects focusing on acute organ traumas, vascular damage, and cancer immunotherapy. The company's lead product candidate is Traumakine, a recombinant human IFN beta-1a, which is in Phase III clinical trial for the treatment of acute respiratory distress syndrome (ARDS). It also develops Clevegen, a pre-clinical immunotherapy candidate, designed to prevent tumor growth and metastasis that targets the tumor immune suppressor molecule; and D-ARDS, a diagnostic tool to estimate ARDS severity and to follow ARDS outcome. Faron Pharmaceuticals Oy has a collaboration with MediCity unit of Turku University Medical School. The company was founded in 2003 and is headquartered in Turku, Finland.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Phone+358-2-4695151
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees18
OptionableNot Optionable
Faron Pharmaceuticals Oy (LON:FARN) Frequently Asked Questions
What is Faron Pharmaceuticals Oy's stock symbol?
Faron Pharmaceuticals Oy trades on the London Stock Exchange (LON) under the ticker symbol "FARN."
Has Faron Pharmaceuticals Oy been receiving favorable news coverage?
News stories about FARN stock have trended neutral on Wednesday, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Faron Pharmaceuticals Oy earned a news sentiment score of 0.3 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the company's share price in the near future.
Who are some of Faron Pharmaceuticals Oy's key competitors?
Some companies that are related to Faron Pharmaceuticals Oy include 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Almirall (LBTSF), AorTech International (AOR), Arix Bioscience (ARIX), Arno Therapeutics (ARNI), Axim Biotechnologies (AXIM), Biocure Technology (CURE), Biotest (BIO), Bioventix (BVXP) and BTG (BTG).
Who are Faron Pharmaceuticals Oy's key executives?
Faron Pharmaceuticals Oy's management team includes the folowing people:
- Mr. Yrjö Erik Kristian Wichmann, CFO & Exec. Director (Age 61)
- Dr. Juho Markku Jalkanen M.D., MSc, VP of Bus. Devel. (Age 41)
- Dr. Markku Tapani Jalkanen Ph.D., Founder, CEO & Exec. Director (Age 64)
- Dr. Mikael Maksimow Ph.D., VP of Operations (Age 43)
- Dr. Matti Karvonen, Chief Medical Officer & VP of Drug Devel.
How do I buy shares of Faron Pharmaceuticals Oy?
Shares of FARN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Faron Pharmaceuticals Oy's stock price today?
One share of FARN stock can currently be purchased for approximately GBX 58.
What is Faron Pharmaceuticals Oy's official website?
How can I contact Faron Pharmaceuticals Oy?
Faron Pharmaceuticals Oy's mailing address is Intelligate, Joukahaisenkatu 6, TURKU, 20520, Finland. The company can be reached via phone at +358-2-4695151.
MarketBeat Community Rating for Faron Pharmaceuticals Oy (LON FARN)
MarketBeat's community ratings are surveys of what our community members think about Faron Pharmaceuticals Oy and other stocks. Vote "Outperform" if you believe FARN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FARN will underperform the S&P 500 over the long term. You may vote once every thirty days.
